Regenerative medicine is a branch of medicine that focuses on repairing, replacing, or regenerating damaged or diseased tissues, organs, and cells in the body. Regenerative medicine focuses on helping the body heal itself, rather than managing symptoms or replacing damaged tissues or organs.
Some examples include Bioengineered Tissues, Amniotic Membrane Grafts, Stem Cell Therapy and PRP.
Regenerative medicine has been one of the most important breakthroughs in wound care over the past decade, and some view it as the ideal blend of effectiveness and convenience. Technologies such as Amniotic Membranes have revolutionized the wound care space.
Providing a natural scaffold rich in growth factors, collagen, and anti-inflammatory proteins, these regenerative treatments can promote cell migration, stimulate tissue regeneration, and create a protective barrier that reduces infection risk and moisture loss, which can accelerate the healing process.
In a randomized controlled trial published in Advances in Wound Care (2015), Serena et al. demonstrated that patients with diabetic foot ulcers treated with dehydrated human amnion/chorion membrane (dHACM) allografts showed a significantly higher rate of complete healing compared to those treated with standard care. The study reported that 70% of the wounds treated with dHACM healed within 12 weeks, compared to 50% in the control group.
Reference: Serena, T. E., Carter, M. J., Le, L. T., Sabo, M. J., & DiMarco, D. T. (2015). A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Advances in Wound Care, 4(8), 543-551.
A study published in Wound Repair and Regeneration (2014) by Zelen et al. investigated the effectiveness of dehydrated amniotic membrane allografts in the treatment of venous leg ulcers. The results showed that 60% of patients treated with the amniotic membrane grafts achieved complete wound closure within 12 weeks, compared to 35% in the control group receiving standard wound care.
Reference: Zelen, C. M., Snyder, R. J., Serena, T. E., Li, W. W., & Fetterolf, D. E. (2014). A prospective, randomized, controlled, multi-center clinical trial comparing dehydrated amniotic membrane allograft and standard of care for the closure of chronic diabetic foot ulcers. Wound Repair and Regeneration, 22(4), 688-693.
In a 2017 study published in Wounds: A Compendium of Clinical Research and Practice, Smiell et al. evaluated the use of cryopreserved amniotic membrane in treating chronic pressure ulcers. The study found that 68% of patients treated with amniotic membrane allografts achieved significant wound healing compared to 45% of those treated with conventional care alone.
Reference: Smiell, J. M., Sabolinski, M. L., Scherer, S. S., & Prussak, J. (2017). A case series evaluating the clinical outcomes of a hypothermically stored amniotic membrane for the treatment of chronic wounds. Wounds, 29(7), 204-210.
A study published in Stem Cells Translational Medicine demonstrated the efficacy of mesenchymal stem cells (MSCs) in improving healing of chronic diabetic wounds. The study showed that MSC treatment led to faster wound closure, reduced inflammation, and enhanced tissue regeneration in diabetic patients with non-healing wounds.
Reference: Stem Cells Translational Medicine, 2015; 4(11): 1191-1199.
A clinical trial registered on ClinicalTrials.gov (Identifier: NCT02619877) evaluated the use of autologous stem cell therapy for treating chronic non-healing ulcers. Preliminary results showed significant improvements in wound closure, skin regeneration, and patient outcomes compared to standard care.
Reference: ClinicalTrials.gov Identifier: NCT02619877
Clinical Trial on Amniotic Membrane Grafts for Diabetic Foot Ulcers (NCT02209051) This randomized clinical trial evaluated the use of dehydrated human amniotic membrane allografts (dHAMA) for treating diabetic foot ulcers. The study found that patients treated with the amniotic membrane graft experienced faster wound healing and better overall outcomes compared to the control group receiving standard care.
Reference: ClinicalTrials.gov Identifier: NCT02209051
Clinical Trial on Amniotic Membrane Grafts for Venous Leg Ulcers (NCT01753048). This trial assessed the effectiveness of cryopreserved amniotic membrane grafts in healing chronic venous leg ulcers. Results showed that patients treated with the amniotic membrane had significantly improved wound closure rates and reduced healing time compared to conventional wound care treatments.
Reference: ClinicalTrials.gov Identifier: NCT01753048
Disclaimer: This website is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis, treatment, and guidance specific to your medical needs. Do not rely on this information for making healthcare decisions.